1 / 11

A torvastatin in F actorial with O mega-3 fatty acid R isk R eduction in D iabetes

…in an academic collaboration with. A torvastatin in F actorial with O mega-3 fatty acid R isk R eduction in D iabetes. Collaborative academic and pharmaceutical study F unded by Pfizer, with data owned, analysed and reported by the University of Oxford Diabetes Trials Unit (DTU)

yule
Download Presentation

A torvastatin in F actorial with O mega-3 fatty acid R isk R eduction in D iabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. …in an academic collaboration with Atorvastatin in Factorial withOmega-3 fatty acid RiskReduction in Diabetes

  2. Collaborative academic and pharmaceutical study Funded by Pfizer, with data owned, analysed and reported by the University of Oxford Diabetes Trials Unit (DTU) Multi-centre primary prevention trial in 1,000 patients with type 2 diabetes Double-blind, placebo-controlled 2 x 2 factorial randomisation to Atorvastatin (Lipitor 20 mg/day) Omega 3 PUFA (Omacor 2g/day) 70 UK clinical centres, one year follow-up Trial Design

  3. Trial Organisation Steering Committee Overall responsibility for scientific, professionaland operational conduct of the study Diabetes Trials Unit Study Design and Protocol Dev. Co-ordinating Centre Investigator agreements Ethical/regulatory approval Data collection and management Protocol/clinical queries Statistical analysis/publication Pfizer UK Protocol development Regulatory aspects Study medication On-site Monitoring SAE reporting 70 Clinical Centres DTU CentralLaboratory

  4. To determine the: Range of estimated CHD risk levels typically seen in people with type 2 diabetes in UK general practice Proportion whose estimated ten-year CHD risk can be reduced below 15% with a 20 mg of atorvastatin or 1.8 g omega-3 PUFA/day Degree to which atorvastatin and omega-3 PUFA in combination have additive effects Extent to which therapy adherence can be enhanced using a simple behavioural intervention Aims

  5. Aged 18 years and above Have had type 2 diabetes for at least 3 months Not known to have had a cardiovascular event Have provided written informed consent Inclusion Criteria

  6. Taking prescribed lipid lowering therapy Triglycerides ≥8.0 mmol/L Have specific contraindications toatorvastatin or omega-3 PUFA Have participated in a clinical trialwithin the last 3 months Are pregnant or lactating females Exclusion Criteria

  7. 2 x 2 Factorial Randomisation Atorvastatin (20 mg ) AtorvastatinPlacebo 500 Omega-3 Omega-3Omega-3 (250)(250) AtorvastatinPlacebo500 Placebo Placebo Placebo (250)(250) 500 500 1,000 Atorvastatin Placebo patientsin total Omega-3PUFA (1.8 g)

  8. Primary Objectives • Proportion of subjects whose LDL levels are<2.6 mmol/L at four months • Proportion of subjects whose triglycerides are<1.5 mmol/L at four months

  9. Secondary Objectives • Proportion of subjects with LDL levels<2.6 mmol/L at one year • Proportion of subjects with triglycerides<1.5 mmol/L at one year • Proportion (%) of subjects with estimated ten-year CHD risk <15% at 16 weeks and one year • Study medication adherenceat 16 weeks and at one year • Health economic assessmentat 16 weeks and at one year

  10. Visit 1: week -2 Recruitment Visit 2: week 0 Randomisation Visit 3: week 16 Four month evaluation Visit 4: week 18 Additional medication* Adherence study Visit 5: week 32 Routine Follow up Visit 6: week 52 One year evaluation End of study * Patients whose estimated CHD risk remains greater than 15% at four months will receive an additional tablet containing 20 mg atorvastatin, whilst the remainder will receive an additional placebo tablet, in double-blind fashion. Visit Schedule

  11. Trial Schedule • Study commenced in November 2004 • One year recruitment in 70 UK practices • One year follow-up for all subjects • Results expected late 2006 • Contact: • Email: aforrd@dtu.ox.ac.uk • Phone: 01865 857 246 • Fax: 01865 857 256 • Web site: www.dtu.ox.ac.uk/aforrd

More Related